Want to see JAZZ full AI Analyst Report?
Revenue by Segment
Provides insight into how different business segments contribute to total revenue, revealing strategic priorities and areas of growth or risk within the company’s diverse portfolio.
Oncology has clearly transitioned from a smaller contributor to the company’s fastest‑growing engine, with accelerating quarterly gains in 2025–26 tied to Zepzelca, Midevo and ZYHERA and near‑term regulatory/catalyst tailwinds; Neuroscience remains the larger, seasonal base but shows Q1 troughs and is exposed to looming H2 headwinds in the oxybate/sleep market. Watch margin impact: revenue mix is shifting toward royalty‑bearing oncology and new launches, supporting top‑line momentum but putting pressure on non‑GAAP gross margins.
JAZZ Revenue by Segment
| Date | Neuroscience | Oncology |
|---|---|---|
| Jun 30, 2026 | $710.90M | $362.30M |
| Mar 31, 2026 | $689.20M | $333.40M |
| Dec 31, 2025 | $791.86M | $337.28M |
| Sep 30, 2025 | $774.43M | $287.84M |
| Jun 30, 2025 | $707.01M | $274.15M |
| Mar 31, 2025 | $605.19M | $229.45M |
| Dec 31, 2024 | $730.47M | $291.76M |
| Sep 30, 2024 | $702.72M | $284.75M |
| Jun 30, 2024 | $684.14M | $277.31M |
| Mar 31, 2024 | $580.98M | $257.55M |
| Dec 31, 2023 | $689.50M | $273.75M |
| Sep 30, 2023 | $675.08M | $260.41M |
| Jun 30, 2023 | $691.37M | $252.21M |
| Mar 31, 2023 | $651.90M | $228.89M |
| Dec 31, 2022 | $740.60M | $223.86M |
| Sep 30, 2022 | $711.41M | $223.35M |
| Jun 30, 2022 | $696.84M | $229.82M |
| Mar 31, 2022 | $612.09M | $196.80M |
| Dec 31, 2021 | $684.79M | $207.07M |
| Sep 30, 2021 | $646.12M | $184.78M |
| Jun 30, 2021 | $581.91M | $163.79M |
| Mar 31, 2021 | $422.57M | $178.18M |
| Dec 31, 2020 | $463.25M | $196.46M |
| Sep 30, 2020 | $456.93M | $138.15M |
| Jun 30, 2020 | $455.39M | $138.15M |
| Mar 31, 2020 | $409.80M | $117.88M |